Latest period
$2.18M
YoY change
-51.9%
5Y CAGR
+27.8%
Peak year (2024)
$5.35M
Latest annual
$2.57M
Stock-Based Compensation history chart for Spruce Biosciences (SPRB) from 2018 to 2025
Latest: $2.57M
Stock-Based Compensation growth chart for Spruce Biosciences (SPRB) from 2018 to 2025
Latest: -51.9%
Stock-Based Compensation history table for Spruce Biosciences (SPRB) from 2018 to 2025
| 2025 | $2.57M | -51.9% | −$2.77M | ||
| 2024 | $5.35M | +15.7% | +$726.00K | ||
| 2023 | $4.62M | — | +$4.62M | ||
| 2022 | $0.00 | -100.0% | −$3.96M | ||
| 2021 | $3.96M | +424.2% | +$3.20M | ||
| 2020 | $755.00K | +285.2% | +$559.00K | ||
| 2019 | $196.00K | +94.1% | +$95.00K | ||
| 2018 | $101.00K | — | — |
- 2025$2.57M-51.9%
- 2024$5.35M+15.7%
- 2023$4.62M—
- 2022$0.00-100.0%
- 2021$3.96M+424.2%
- 2020$755.00K+285.2%
- 2019$196.00K+94.1%
- 2018$101.00K—
Stock-Based Compensation values are taken from Spruce Biosciences's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at Spruce Biosciences (SPRB)
Stock-Based Compensation for Spruce Biosciences (SPRB): headline value $2.18M · YoY -51.9%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Spruce Biosciences (SPRB) reported stock-based compensation of $2.57M – plunged 51.9% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Spruce Biosciences stock-based compensation compounded at +27.8% per year, with mixed annual results across the window.
The record annual stock-based compensation stands at $5.35M, reached in 2024; the historical low of $0.00 was recorded in 2022.
Spruce Biosciences Stock-Based Compensation by Year
Spruce Biosciences Stock-Based Compensation 2025: $2.57M
2025's stock-based compensation for Spruce Biosciences came in at $2.57M, plunged 51.9% below 2024.
Spruce Biosciences Stock-Based Compensation 2024: $5.35M
Spruce Biosciences posted stock-based compensation of $5.35M in 2024, grew 15.7% from 2023. This figure represents the highest annual value in the available history.
Spruce Biosciences Stock-Based Compensation 2023: $4.62M
Spruce Biosciences stock-based compensation in 2023 was $4.62M.
Spruce Biosciences Stock-Based Compensation 2022: $0.00
Spruce Biosciences stock-based compensation in 2022 was $0.00, plunged 100.0% below 2021. This figure represents the lowest annual value in the available history.
Spruce Biosciences Stock-Based Compensation 2021: $3.96M
Spruce Biosciences stock-based compensation in 2021 was $3.96M.
See more financial history for Spruce Biosciences (SPRB).
Sector peers by Stock-Based Compensation
Healthcare peers of Spruce Biosciences (SPRB), ranked by their latest stock-based compensation
| $1.35B | |
| $971.00M | |
| $955.00M | |
| $626.00M | |
| $0.00 | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $971.00M
- $955.00M
- $626.00M
- $0.00
- $0.00
- $0.00
- $0.00
Frequently asked questions
Spruce Biosciences (SPRB) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation